Sunday, May 24, 2026
ISSN 2765-8767
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us

A COVID-19 variant ‘more infectious than the delta variant’ will hit U.S. in 2-4 months, according to CDC

Dr. Robert Redfield, the former director of the Centers for Disease Control and Prevention, predicted that the fall will have a dark turn in the coronavirus pandemic.

Redfield said on Fox News Channel’s “The Story” that he thinks the coronavirus will continue to replicate quickly among humans, and so the risk of variant evolution is high.

“You know we dealt with the U.K. variant; everyone thought that was pretty bad, it was twice as infectious, but lo and behold three, four months later we had the delta variant and now it’s a dominant variant in the United States,” Redfield said.

He then predicted that there will be another, more dangerous coronavirus variant by the fall.

“Within, you know two, three, four months we’re going to have another variant and that variant’s going to be more infectious than the delta variant,” Redfield said.

Redfield said the coronavirus became one of the most infectious viruses in humans, which allowed it to mutate quicker.

Source: Deseret News

Daily Remedy

Daily Remedy

Dr. Jay K Joshi serves as the editor-in-chief of Daily Remedy. He is a serial entrepreneur and sought after thought-leader for matters related to healthcare innovation and medical jurisprudence. He has published articles on a variety of healthcare topics in both peer-reviewed journals and trade publications. His legal writings include amicus curiae briefs prepared for prominent federal healthcare cases.

Videos

Policy Shift in Peptide Regulation

FDA Evaluation of Certain Bulk Drug Substances in Compounding: Clinical Interpretation

FDA Evaluation of Certain Bulk Drug Substances in Compounding: Clinical Interpretation

Clinicians increasingly encounter patients using or requesting peptide-based therapies sourced through compounding pharmacies. The U.S. Food and Drug Administration has identified a subset of bulk drug substances, including certain peptides, that may present significant safety risks when used in compounded formulations. The clinical question is whether these regulatory signals reflect meaningful patient-level risk and how they should influence prescribing behavior. This matters because compounded peptides often sit outside traditional approval pathways, creating uncertainty around quality, dosing consistency, and safety. Understanding...

Read more

Join Our Newsletter!